Login
Navigate Fool.com
Will DNDN beat
the market?

Dendreon Corp (NASDAQ: DNDN)

Community Rating: 2 Stars: Unattractive

2.10 -0.04 (-1.87%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.14
Previous Close $2.14
Daily Range $2.08 - $2.19
52-Week Range $1.81 - $5.38
Market Cap $335.9M
P/E Ratio -1.25
Dividend (Yield) $0.00 (0.0%)
Volume 1,532,906
Average Daily Volume 2,042,776
Current FY EPS -$0.77

How do you think DNDN
will perform against the market?

Top DNDN Bull/Bear Pitches

 

Paigowpete (0)
Submitted October 13, 2011

Sales should improve dramatically--medicare approved, centers set,reached their goal on centers and everything should follow--earnings growth will follow

0 Replies Reply Report this Post
 

JDR524 (< 20)
Submitted June 6, 2010

As a Medical Oncologist, I will be Dendreon's primary customer. Right now, I have many reservations about Provenge including price (the old guys I take care of mostly lose interest when I tell them … More

6 Replies Reply Report this Post

News & Commentary

Are Cancer Vaccines Worth an Investment?

Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.

August 29th Options Now Available For Dendreon

3 Reasons to Buy Medivation Inc.

Medivation is mid-cap biopharma that looks to have a promising future based on the commercial performance of its prostate cancer drug. Here's what you need to know.

Is There Any Hope for Dendreon?

With large debt and a history of net losses, is it too little too late to turn around Dendreon?

Predicting Dendreon's Next CEO's Future

Its time to play Fool in the blank

Is Pfizer Putting the Car-T Before the Horse?

Pfizer has moved to establish a good preclinical presence in a promising emerging cancer therapy class

Is Gene Therapy Medicine's Next Big Thing?

Bluebird Bio (BLUE) is advancing gene therapies through clinic using technology that Celgene (CELG) thinks could someday be used to treat cancer.

Dendreon's CEO Exits: Is this the Beginning of the End?

Dendreon CEO John Johnson announced yesterday that he is stepping down for "personal reasons." His departure comes ahead of a large company debt payment. Could Dendreon be on the precipice of bankruptcy?

Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon

Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.

Why Wall Street Hates Dendreon Corp.

Stocks with heavy short interest might signal that something is terribly wrong with a company. Dendreon Corp. sports one of the highest short interests among health-care stocks. Why are short-sellers so bearish on this small-cap biotech?

See More DNDN News...

Sector

Healthcare

Industry

Drugs

Dendreon Corp (DNDN) Description

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Website: http://www.dendreon.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks